ArticleBritish journal of pharmacology2014
Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge.
Article in British journal of pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis.International journal of chronic obstructive pulmonary diseasePooled it
- Mechanisms, Efficacy, Safety, and Pharmacoeconomics of Low-Dose, Long-Term Macrolide Antibiotics in the Treatment of Chronic Obstructive Pulmonary Disease: A Review.International journal of chronic obstructive pulmonary disease · 2026Review
- Immune cell targeted fumaric esters support a role of GPR109A as a primary target of monomethyl fumarate in vivo.Inflammopharmacology · 2023Article
- The Azithromycin Pro-Drug CSY5669 Boosts Bacterial Killing While Attenuating Lung Inflammation Associated with Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2022Article
- Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Immunomodulation Mediated by Azithromycin in Experimental Periapical Inflammation.Journal of endodontics · 2020Article
- Pharmacological plasticity-How do you hit a moving target?Pharmacology research & perspectives · 2019Review
- Macrolide derivatives reduce proinflammatory macrophage activation and macrophage-mediated neurotoxicity.CNS neuroscience & therapeutics · 2019Article
- Azithromycin Affords Neuroprotection in Rat Undergone Transient Focal Cerebral Ischemia.Frontiers in neuroscience · 2019Article
- Combining MucilAir™ and VitrocellPharmaceutics · 2018Article
- Autoinflammatory disease in the lung.Immunology · 2018Review
- Rhesus θ-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment.American journal of respiratory cell and molecular biology · 2018Article
- CHAC1 Is Differentially Expressed in Normal and Cystic Fibrosis Bronchial Epithelial Cells and Regulates the Inflammatory Response Induced byFrontiers in immunology · 2018Article
- Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease.Therapeutic advances in respiratory disease · 2017Review
- Predictive screening of M1 and M2 macrophages reveals the immunomodulatory effectiveness of post spinal cord injury azithromycin treatment.Scientific reports · 2017Article
- Longitudinal assessment of bleomycin-induced lung fibrosis by Micro-CT correlates with histological evaluation in mice.Multidisciplinary respiratory medicine · 2017Article
- In vivo monitoring of lung inflammation in CFTR-deficient mice.Journal of translational medicine · 2016Article
- Novel approaches to the management of noneosinophilic asthma.Therapeutic advances in respiratory disease · 2016Review
- Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity.Scientific reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeAzithromycin is a macrolide antibiotic with anti-inflammatory and immunomodulating effects. Long-term azithromycin therapy in patients with chronic lung diseases such as cystic fibrosis has been associated with increased antimicrobial resistance, emergence of hypermutable strains, ototoxicity and cardiac toxicity. The aim of this study was to assess the anti-inflammatory effects of the non-antibiotic azithromycin derivative CSY0073. EXPERIMENTAL APPROACH: We compared the effects of CSY0073 with those of azithromycin in experiments on bacterial cultures, Pseudomonas aeruginosa biofilm, lung cells and mice challenged intranasally with P. aeruginosa LPS. KEY
resultsIn contrast to azithromycin, CSY0073 did not inhibit the growth of P. aeruginosa, Staphylococcus aureus or Haemophilus influenzae and had no effect on an established P. aeruginosa biofilm. Bronchoalveolar lavage (BAL) fluids and lung homogenates collected after the LPS challenge in mice showed that CSY0073 and azithromycin (200 mg·kg(-1), i.p.) decreased neutrophil counts at 24 h and TNF-α, CXCL1 and CXCL2 levels in the BAL fluid after 3 h and IL-6, CXCL2 and IL-1β levels in the lung after 3 h compared with the vehicle. However, only azithromycin reduced IL-1β levels in the lung 24 h post LPS challenge. CSY0073 and azithromycin similarly diminished the production of pro-inflammatory cytokines by macrophages, but not lung epithelial cells, exposed to P. aeruginosa LPS. CONCLUSIONS AND IMPLICATIONS: Unlike azithromycin, CSY0073 had no antibacterial effects but it did have a similar anti-inflammatory profile to that of azithromycin. Hence, CSY0073 may have potential as a long-term treatment for patients with chronic lung diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.